GlassScriptPhysician profile
Ji H Han
NPI 1801937750
$14,184.06
in general payments reported to CMS, 2019-2025
45 companies · $1,380 in 2025
The $1,380 reported for 2025 was more than what a typical Interventional Pain Medicine provider received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,770 · 2020: $2,260 · 2021: $2,683 · 2022: $1,905 · 2023: $2,169 · 2024: $2,016 · 2025: $1,380.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,566.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,565.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $4,935.34 | 2019-2025 | Proclaim, Axium, Octrode |
| Scilex Pharmaceuticals INC. | $1,346.19 | 2019-2025 | Ztlido |
| Redhill Biopharma INC. | $1,073.64 | 2020-2022 | |
| Boston Scientific Corporation | $785.72 | 2019-2024 | Wavewriter Alpha Prime 16 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $783.27 | 2019-2025 | Relistor |
| Nevro Corp. | $568.83 | 2019-2024 | Senza |
| Medtronic, INC. | $494.73 | 2023-2025 | Ffrangio, Intellis Adaptivestim, O-Arm |
| Collegium Pharmaceutical, INC. | $430.99 | 2019-2025 | Xtampza, Belbuca |
| Abbvie INC. | $329.76 | 2021-2024 | |
| Valinor Pharma, LLC | $329.59 | 2023-2025 | Movantik |
| Horizon Therapeutics Plc | $318.39 | 2019-2022 | |
| Forte Bio-Pharma LLC | $311.06 | 2022-2025 | Prolate, Nalocet, Tanlor |
| Allergan, INC. | $275.10 | 2019-2022 | |
| Kowa Pharmaceuticals America, INC. | $264.97 | 2022-2023 | Seglentis |
| Globus Medical, INC. | $202.66 | 2025 | Senza, Omnia |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ji Han listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.